dyslipidaemia - Robuta Search

https://www.nice.org.uk/guidance/ta394 Overview | Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | Guidance... Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults overview evolocumab treating primary hypercholesterolaemia https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.996467/full Frontiers | Red meat consumption and risk for dyslipidaemia and inflammation: A systematic review... Aim:The study (PROSPERO: CRD42021240905) aims to reveal the relationships among red meat, serum lipids and inflammatory biomarkers.Methods and Results: PubMe... red meat https://pmc.ncbi.nlm.nih.gov/articles/PMC11019316/ Managing dyslipidaemia in patients with chronic kidney disease - PMC Patients with CKD are at increased risk for cardiovascular events. Clinical studies suggest statins reduce all-cause mortality and cardiovascular events in... chronic kidney disease in patients managing dyslipidaemia pmc https://www.escardio.org/communities/councils/cardiology-practice/scientific-documents-and-publications/ejournal/volume-19/dyslipidaemia-after-heart-transplantation/ Dyslipidaemia after heart transplantation dyslipidaemia heart transplantation https://www.nice.org.uk/guidance/ta393/chapter/1-Recommendations 1 Recommendations | Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |... Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults 1 recommendations alirocumab treating primary https://pmc.ncbi.nlm.nih.gov/articles/PMC10825570/ Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors - PMC Apolipoprotein C3 (apoC3) and angiopoietin-like protein 3 (ANGPTL3) inhibit lipolysis by lipoprotein lipase and may influence the secretion and uptake of... advances dyslipidaemia treatments focusing https://pmc.ncbi.nlm.nih.gov/articles/PMC11114474/ Dyslipidaemia management in pregnant patients: a 2024 update - PMC Over several decades, the approach to treating dyslipidaemias during pregnancy remains essentially unchanged. The lack of advancement in this field is mostly... dyslipidaemia management 2024 update pregnant patients pmc https://www.nice.org.uk/guidance/ta393/chapter/the-technology 2 The technology | Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |... Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults 2 the technology alirocumab